Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€22.42

€22.42

3.030%
0.66
3.030%
€100.00
 
26.04.24 / Tradegate WKN: A2PY7M / Name: Schrodinger Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Schrodinger Inc. Stock

Schrodinger Inc. dominated the market today, gaining €0.66 (3.030%).
Currently there is a rather positive sentiment for Schrodinger Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 100 € there is potential for a 346.03% increase which would mean more than doubling the current price of 22.42 € for Schrodinger Inc..
So far the community has only identified positive things for Schrodinger Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Schrodinger Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-23

Schrodinger Inc., a company operating in the industry, appears to have experienced notable changes in its financial performance over the past few years. Upon an initial review of the available financial statements, it can be observed that the company is managing significant assets and revenues. However, it is also facing challenges in various aspects of its operations, including increasing expenses and fluctuating cash flow.

Growth in Total Assets: Schrodinger's total assets have been increasing consistently over the past few years. From 2020 to 2022, total assets grew from $746 million to $838 million, which demonstrates the company's ability to grow its asset base.

Increase in Revenue: Revenue has been steadily rising for Schrodinger, with total revenue increasing from $108 million in 2020 to $180 million in 2022. This upward trend indicates that the company has been successful in expanding its market presence and growing its business.

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2024, the company

Schrödinger to Announce First Quarter 2024 Financial Results on May 1: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger to Announce First Quarter 2024 Financial Results on May 1


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2024 financial results on

Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1